The trichothecene mycotoxins are a family of over 200 sesquiterpenoid metabolites that are produced by several fungal genera in food and the environment (Grove, 2007) . Notably, fusaria are capable of elaborating trichothecenes in cereals grown in temperate regions of the world (Creppy, 2002) . Because such grain contamination is often unpreventable and trichothecenes survive milling and processing, there is considerable concern over potential adverse health effects resulting from human and animal exposure to these toxins, . Deoxynivalenol (DON), an 8-ketotrichothecene associated with Fusarium head blight (''scab'') in wheat and barley, is the most commonly detected foodborne trichothecene (Lombaert et al., 2003; Trucksess et al., 1995) .
Following oral exposure, DON is rapidly absorbed into the tissues of monogastric animals and can reach peak plasma concentrations within 15-30 min of oral dosing Prelusky et al., 1988) . It is detoxified through deepoxidation by gut microflora (He et al., 1992) and glucuronidation in liver (Obol'skii et al., 1998) . Acute high dose exposure to DON can cause feed refusal or emesis in sensitive species (Pestka et al., 1987) . In addition, animals are sensitive to retardation of growth and weight gain when chronically exposed to DON (Forsell et al., 1986; Rotter et al., 1992; Iverson et al., 1995) .
DON can rapidly and transiently upregulate production of proinflammatory cytokines in vivo (Dong et al., 1994; AzconaOlivera et al., 1995; Zhou et al., 1997; Wong et al., 1998) with elevation of interleukin (IL)-6 being most remarkable Pestka and Amuzie, 2008 ). An integrated model for aberrant cytokine upregulation based on in vitro and in vivo observations predicts that DON first binds to ribosomes, initiates phosphorylation of ribosome-associated mitogenactivated protein kinases, leading to selective transcription, increased mRNA stability, and increased translation of cytokine mRNA (Bae and Pestka, 2008; Chung et al., 2003; Zhou et al., 2003 Zhou et al., , 2005 . DON-induced upregulation of proinflammatory cytokines has the potential to evoke pleiotropic effects, some of which could likely mediate its toxicity.
Adverse growth and immune effects in rodents are considered critical end points in DON risk assessments and these have been used as a basis for establishing regulatory standards (Tritscher and Page, 2004) . The mechanism(s) for DON-induced impairment of growth and weight gain reduction are not well understood, leading to uncertainties in human risk estimation. It has been previously suggested that DON-induced growth effects are caused by feed refusal (Prelusky, 1997) . The putative role of feed refusal might be questioned for several reasons. First, although feed refusal could result from altered central appetite control following serotonin dysregulation (Fitzpatrick et al., 1988; Prelusky, 1993; Prelusky and Trenholm, 1993) , serum serotonin concentrations remain unchanged in animal models of DON exposure (Prelusky, 1994) , making its systemic relevance less clear. Second, rodent studies using a serotonin antagonist (cyproheptadine) did not support a central role of feed refusal in DON-induced weight reduction, leading to the conclusion that DON's weight effects might be secondary to other pharmacological actions and influenced by factors other than reduced feed intake. Finally, feeding studies by our group (Forsell et al., 1986) and Canadian researchers (Iverson et al., 1995) failed to demonstrate a strong correlation between weight reduction and feed refusal in DON-fed mice, particularly at lower dietary concentrations (10 ppm), thus corroborating the aforementioned conclusions from serotonin studies.
An alternative hypothesis for DON-induced weight reduction can be derived from human and animal studies of proinflammatory cytokine signaling, particularly with regards to IL-6, IL-1b, and tumor necrosis factor (TNF)-a. First, overexpression of proinflammatory cytokines like IL-6 (De Benedetti et al., 1997) and TNF-a (Probert et al., 1996) in mice has been associated with a reduction in weight gain. Second, deficiencies in both IL-6 (Wallenius et al., 2002) and IL-1 receptor (Garcia et al., 2006) in mice cause increased weight gain, whereas TNF receptor-deficient mice exhibit high food conversion efficiency (i.e., increased weight gain per gram food consumed) (Pestka and Zhou, 2002) . Third, the weight increase in IL-6 deficient mice is reversible with IL-6 replacement (Wallenius et al., 2002) . Finally, marked increases in plasma IL-6 have been observed during human exercise and these have been suggested to mediate the metabolic benefits that include weight loss (Pedersen and Febbraio, 2008) . Taken together, these studies suggest that cytokine upregulation might be another mechanism contributing to impaired growth and weight gain observed in DON-exposed mice.
Multiple, complementary pathways might exist for cytokinemediated growth/weight reduction. Cytokine signaling studies have resulted in the identification of a variety of SH2 domaincontaining proteins, all of which negatively regulate cytokine signaling thereby decreasing potential for tissue injury from an overactive inflammatory response (Endo et al., 1997; Naka et al., 1997; Starr et al., 1997; Yoshimura et al., 1995) . These cytokine-inducible inhibitors of cytokine signaling, better known as suppressors of cytokine signaling (SOCS), are expressed in a tissue-specific manner (Starr et al., 1997) to finely regulate various members of the cytokine receptor superfamily. Members of this group include the wellcharacterized CIS (cytokine-inducible SH2 domain protein), SOCS1, SOCS2, and SOCS3 and the lesser understood SOCS4, SOCS5, SOCS6, and SOCS7.
In addition to downregulating cytokine signaling, many SOCS impair growth factor signaling . Interestingly, growth hormone (GH) binds to GH receptor, a member of the cytokine receptor superfamily (Bazan, 1989) that is susceptible to SOCS-dependent impairment. In support of this contention, treatment with proinflammatory cytokines or the inflammagen lipopolysaccharide (LPS) inhibits GHinduced gene expression in whole liver (Mao et al., 1999; Yumet et al., 2006) and in isolated mammalian hepatocytes (Ahmed et al., 2007; Bergad et al., 2000; Boisclair et al., 2000; Shumate et al., 2005; Thissen and Verniers, 1997; Wolf et al., 1996) in a SOCS-dependent manner (Chen et al., 2007; Denson et al., 2003; Yumet et al., 2006) . This suggests that SOCS proteins might mediate crosstalk between proinflammatory cytokine signaling and GH signaling. The phenomenon of inflammagen-induced impairment of GH signaling has been described as GH resistance and appears to involve marked reduction of circulating insulin-like growth factor 1 (IGF1) .
Based on the aforementioned studies, the potential exists for DON-induced cytokine upregulation to mediate SOCS upregulation, which might, in turn, minimize tissue injury from inflammatory response, impair GH signaling and reduce growth. In this study, we hypothesized that acute DON exposure will induce SOCS expression in the mouse. To test this hypothesis, female B6C3F1 (3-4 weeks) were treated orally with DON over a range of doses and then expression of proinflammatory cytokines related to that of SOCS at various time intervals in different tissues. Our results showed that DON exposure rapidly (1 h) induced expression of the proinflammatory cytokines TNF-a and IL-6 in organs, with concurrent or subsequent upregulated gene expression for CIS, SOCS1, and SOCS2 and to the greatest extent, SOCS3. SOCS upregulation of in DON-exposed mice was also associated with a 75% suppression of GH-inducible insulin-like growth factor acid labile subunit, consistent with the potential for SOCS to interfere with GH signaling and minimize cytokine-mediated injury.
MATERIALS AND METHODS
Laboratory animals. Pathogen-free female B6C3F1 mice (3-4 weeks) (Charles River laboratories, Portage, MI) were randomly assigned to experimental groups (n 5) and housed in polycarbonate boxes containing Cell-Sorb Plus bedding (A & W Products, Cincinnati, OH). Boxes were covered with filter bonnets and mice were provided free access to food (8640 Teklad 22/5 rodent diet, Harlan, Madison, WI) and water. Room lights were set on a 12-h light/dark cycle, and temperature and relative humidity were maintained between 21 and 24°C and 40-55%, respectively. Groups of mice (four to five per group) were maintained according to National Institutes of Health guidelines as overseen by the All University Committee on Animal Use and Care at Michigan State University.
Exposure regimen and tissue collection. DON was purchased from Sigma Chemical Co. (St Louis, MO). For each acute exposure experiment, DON was dissolved in Dulbecco's phosphate-buffered saline (PBS) (SigmaAldrich) to yield an exposure volume of 100-200 ll per mouse for any of the selected DON doses (0.1-12.5 mg/kg bw), whereas equivalent volumes of PBS were used as vehicle control (0 mg/kg bw). Mice were orally gavaged using 278 AMUZIE, SHINOZUKA, AND PESTKA a 22 G intubation needle (Popper and Sons, New Hyde Park, NY). At experiment termination, mice were deeply anesthetized by ip injection with 0.1 ml of 50 mg/ml sodium pentobarbital. The abdominal cavity was opened and then the blood was collected with heparinized syringes via the caudal vena cava, and transferred to centrifuge tubes. Following blood collection, the caudal half of spleen, the caudolateral piece of the lateral lobe of liver and the gastrocnemius muscle were collected, from each mouse for real-time PCR and/ or immunohistochemistry.
Quantitative real-time PCR. Excised tissues for PCR analyses were stored immediately after harvesting in RNAlater (Ambion Inc., Austin, TX). RNA was isolated using Tri Reagent (Molecular Research Center, Inc., Cincinnati, OH). Real-time PCR for CIS1, SOCS1, SOCS2, SOCS3, TNF-a, IL-6, IL-1b, and insulin-like growth factor acid-labile subunit (IGFALS) were performed on an ABI PRISM 7900HT Sequence Detection System, using Taqman One-Step Realtime PCR Master Mix and Assays-on-Demand primer/probe gene expression products according to the manufacturer's protocols (Applied Biosystems, Foster City, NY). Fold change of targets was determined using b2-microglobulin RNA control and a relative quantitation method .
Plasma cytokine analysis. TNF-a, IL-6, monocyte chemotactic protein-1 (MCP-1), interferon-c, IL-10, and IL-12p70 concentrations in plasma were simultaneously determined with a Cytometric Bead Array Mouse Inflammation Kit (BD Biosciences, San Diego, CA) according to manufacturer's instructions using a FACS caliber and BD CBA Analysis Software (BD Bioscience, San Jose, CA).
Plasma DON quantitation. Prior to DON measurement, plasma was separated from blood by centrifugation and diluted (1:7 [vol/vol]) in PBS. Diluted plasma was centrifuged at 15,000 3 g for 10 min. The supernatant fraction was first heated at 100°C for 5 min and then centrifuged at 15,000 3 g for 10 min. The resultant supernatant was used for DON analysis, using a Veratox High Sensitivity (HS) enzyme-linked immunosorbent assay (ELISA) (Neogen, Lansing, MI) with modifications . Briefly, DON horseradish peroxidase conjugates were diluted (1:7 [vol/vol]) in 1% (wt/vol) bovine serum albumin (Sigma) in PBS. Aliquots (100 ll) of DON standards (1-500 ng/ml) or appropriately diluted samples were mixed with 100 ll of diluted enzyme conjugates and then incubated in antibody-coated microtiter wells for 45 min. After incubation, wells were aspirated and washed with distilled water. DON HS substrate (100 ll) was added and further incubated for 20 min before terminating the reaction with 100 ll of stop reagent. Plates were read at 690 nm on an ELISA plate reader (Molecular Devices, Menlo Park, CA). DON concentrations in samples were determined from standard curve using Softmax software (Molecular Devices). Because this ELISA might detect DON as well as some of its metabolites, data were reported as DON equivalents per milliliter.
Immunohistochemistry. Immunohistochemistry for SOCS-3 was performed on 10% (vol/vol) neutral buffered formalin-fixed paraffin-embedded liver sections (5 lm). Briefly, sections were placed in citrate buffer (10mM, pH 6.0) and then placed in a Minichef microwave (Samsung) for 10 min. Microwaved sections were stained with rabbit anti-human CIS3/SOCS-3 monoclonal antibody (clone C204, 1:20; Immuno-Biological Laboratories, Inc., Gunma, Japan) as primary antibody, followed by the avidin-biotin peroxidase complex reaction using VECTASTAIN Elite ABC kit (Vector Laboratories, Burlingame, CA). Positive reactions were visualized after peroxidase-diaminobenzidine (DAB) reaction and counterstaining with hematoxylin.
Statistics. Differences between two groups were determined by Student's t-test, or Mann-Whitney U test when equality of variance failed. Differences among multiple groups were determined by ANOVA using SigmaStat v 3.1 (Jandel Scientific; San Rafael, CA) combined with Student-Neuman-Keul's post hoc test; or by Kruskal-Wallis ANOVA on ranks combined with Dunn's test when normality or equality of variance test failed. Grubb's test (www.graphpad.com) was used to isolate four significant outliers throughout the analysis, each occurring alone within a group of four to five mice. The criterion for significance was p < 0.05.
RESULTS

Effects of DON Dose on SOCS mRNA in the Mouse
Real-time PCR was used to assess the effects of exposure to DON over a dose range of 0.1-12.5 mg/kg bw on the expression of four SOCS mRNAs (CIS, SOCS1, SOCS2, and SOCS3) in spleen, muscle and liver. CIS, SOCS1, SOCS2 and SOCS3 mRNAs were upregulated in spleen by 7-, 25-, 5-, and 35-fold over control, respectively, at the highest DON dose (Fig. 1) . At 1 mg/kg bw mRNAs for these four SOCS were upregulated one-, four-, six-, and sixfold, respectively.
Although CIS mRNA expression was not detectable in muscles of either control or DON-treated mice, DON-induced expression of other SOCS mRNAs, albeit to a much lesser extent than observed in spleen. Muscle SOCS1 mRNA was modestly elevated only at 0.5 mg/kg bw (Fig. 2A) . SOCS2 mRNAs were significantly upregulated (threefold) at 5 and 12.5 mg/kg bw (Fig. 2B ). There was comparatively robust elevation of SOCS3 in muscle (12-fold) at the two highest doses (Fig. 2C ).
There were marked increases of CIS mRNAs in the livers of DON-treated mice, reaching 14-fold at 5 and 12.5 mg/kg bw (Fig. 3A) . Hepatic SOCS1 expression was not detectable in control and DON-treated mice. As in spleen and muscle, SOCS2 was affected least in the liver among all SOCS analyzed with all DON doses causing modest SOCS2 mRNA increases (two-to sixfold) (Fig. 3B) . Hepatic SOCS3 upregulation was the highest among all SOCS analyzed. SOCS3 mRNAs increased with dose, differing significantly from vehicle at 1 mg/kg bw DON (sixfold), 5 mg/kg bw (38-fold), and 12.5 mg/kg bw (108-fold) (Fig. 3C) . Hepatic SOCS3 expression thus appeared to be highly dose dependent.
Kinetics of DON-Induced Cytokine and SOCS Upregulation
The kinetics of DON-induced proinflammatory cytokine mRNA induction was related to SOCS upregulation in the murine spleen and liver. In spleen, DON-induced TNF-a mRNA expression within 1 h, reached peak concentrations at 2 h and returned to basal levels at 4 h (Fig. 4A ). IL-6 mRNA was upregulated and reached peak levels within 2 h but returned to basal level at 4 h after DON exposure (Fig. 4B) . CIS mRNA followed a similar pattern to IL-6, and SOCS3 especially within 1-4 h (Fig. 4C) . SOCS3 mRNA was upregulated as early as 1 h, reaching 20-to 35-fold of control values at 2-3 h and remained significantly upregulated up to 5 h after DON exposure. It was notable that maximum CIS and SOCS3 mRNA expression (2-3 h) corresponded to the peak and onset of decline for both proinflammatory cytokine mRNAs.
In the liver, both TNF-a and IL-6 mRNAs were upregulated within 1 h (Figs. 5A,B) with expression of both peaking within 2 h and declining thereafter. Hepatic CIS and SOCS3 induction peaked at 2 h. mRNAs for SOCS3 remained elevated beyond DON-INDUCED SOCS EXPRESSION 4 h, whereas those for TNF-a and IL-6 returned to near basal levels. Thus, robust proinflammatory cytokine induction appeared to precede hepatic SOCS induction (2 h) in DONtreated mice. SOCS3 mRNA decline was relatively slower than proinflammatory cytokines.
Kinetics of Proinflammatory Cytokine and DON Concentrations in Plasma
To confirm that tissue proinflammatory cytokine upregulation resulted in increasing amounts of circulating cytokines, six plasma proinflammatory cytokines were analyzed with cytometric bead array. TNF-a, IL-6, and MCP-1 were significantly upregulated in DON-treated mice (Fig. 6 and Supplementary Fig. S2 ). TNF-a was modestly upregulated within the first hour of DON exposure, however all cytokines reached peak concentration within 2-3 h of DON exposure. The magnitude of induction at peak of various cytokines indicates a rank order of IL-6 > MCP-1 > TNF-a. All proinflammatory cytokines returned to basal levels by 5 h after DON exposure.
To relate plasma DON elevation to cytokine upregulation in mice, plasma DON was measured with competitive direct ELISA. Data indicated that peak plasma DON concentration was attained within the first hour and declined rapidly thereafter (Fig. 7) , consistent with a plasma half-life of 0.7 h previously reported . At 5-h postexposure, plasma DON concentration was 8% of that observed in the first hour. Interestingly, that rapid elevation of plasma DON and its transient nature seemed to mirror the circulating proinflammatory cytokines induced by DON.
DON Exposure Induces Hepatic SOCS3 Protein Expression
DON-induced SOCS3 mRNA was related to expression of SOCS3 protein in liver using immunohistochemistry. DON did not induce SOCS3 protein expression at 2 h (Fig. 8A ) but caused modest expression at 3 h (Fig. 8B) , however, SOCS3 staining was markedly expressed at 4 and 5 h with the greatest deposits be localizable to centrilobular regions of the liver. (Figs. 8C,D) . Vehicle-exposed mice did not exhibit binding of anti-SOCS3 at 3 h and 5 h (Figs. 8E,F) . Thus, the highest DON dose caused more that a 100-fold increase in SOCS3 mRNA in liver (Fig. 5) at 2-to 3-h postexposure, and a robust protein increase in liver around 4-5 h, suggesting a sequential increase in transcription and translation of hepatic SOCS3.
DON Exposure Suppresses Hepatic IGFALS Expression
Because hepatic SOCS upregulation has been suggested to impair GH-induced IGFALS (Boisclair et al., 2000) , hepatic IGFALS mRNA expression was analyzed in DON-treated mice. DON treatment progressively reduced IGFALS mRNA to 68, 25, and 24% that of naive mice at 1, 3, and 5 h, respectively (Fig. 9) . In comparison, IGFALS mRNA of vehicle-treated mice remained unaffected after 5 h.
DISCUSSION
This is the first report of SOCS induction by a mycotoxin. Recombinant proinflammatory cytokines have been previously shown to induce SOCS proteins, in a tissue-specific manner (Starr et al., 1997) . Bacterial LPS can also induce SOCS (Mao et al., 1999) . SOCS proteins share a conserved SOCS-box in their carboxy-terminal region and a Src homology 2 (SH2) domain that mediates their interactions with other proteins. SOCS family proteins are critically important in the negative regulation of cytokine and growth factor signaling pathways. We have now associated SOCS upregulation with hepatic IGFALS suppression in DON-exposed mice. Thus, DONinduced SOCS expression has the potential to play a regulatory role in signaling pathways mediated by the cytokine receptor superfamily members such as IL-6 and GH that ultimately impact inflammation and growth, respectively (Fig. 10) .
Three mechanisms have been proposed to act either independently, or in concert to achieve the SOCS-induced negative regulation of signaling . These include (1) inhibition of intracytoplasmic signaling kinases (2) receptor binding competition with other intracytoplasmic SH2 domain-containing proteins; and (3) SOCSinitiated proteasomal degradation. SOCS-induced negative regulation of cytokine/growth factor pathways have been demonstrated in numerous in vivo and in vitro investigations involving several species (Croker et al., 2008) . Among the eight known SOCS proteins, the four most well characterized in terms of their physiological roles are CIS, SOCS1, SOCS2, 
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and SOCS3 (Tan and Rabkin, 2005) . Consistent with earlier reports (Starr et al., 1997) , we observed differential tissue expression of these SOCS, both relative to basal expression and DON-induced expression. Furthermore, the suppression of IGFALS in the liver of DON-treated mice indicates that SOCS upregulation might modulate GH signaling in these mice.
CIS was upregulated in the spleen and to a much greater extent in the liver. Notably, CIS inhibits GH signaling in vitro (Ram and Waxman, 1999) , and growth retardation occurs in mice that overexpress CIS (Matsumoto et al., 1999) . Furthermore, CIS is involved in IL-6 inhibition of hepatic GH signaling . Because DON significantly 
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AMUZIE, SHINOZUKA, AND PESTKA induces IL-6, the possibility exists that CIS upregulation could impair hepatic GH signaling and thereby reduce growth.
SOCS1 is well-characterized as an inhibitor of IL-4, IL-6, IL-12, and interferon-c signaling pathways (Ram and Waxman, 1999) but not a GH inhibitor. The robust induction of SOCS1 in spleen might modulate both inflammatory and innate immune responses. The absence of SOCS1 upregulation in the liver of DON-exposed mice suggests that SOCS1 may not play a major role in DON-related hepatic signaling impairment. It was surprising that SOCS1 was nondetectable in the liver of mice, in contrast to another study (Wormald et al., 2006) . This discrepancy might be a result of one or a combination of the following differences: (1) mouse strain (C57BL/6 vs. B6C3F1); (2) PCR method (SYBR green vs. Taqman); (3) stimulus (interferon-c versus DON); and (4) mouse age (7 vs. 4 weeks). Regardless of the cause, it was clear that our method was sufficiently robust to detect SOCS1 upregulation in the spleen.
SOCS2 expression was modestly upregulated in liver, spleen and muscle of DON-treated mice. A potential role of SOCS2 in GH signaling is complicated because both SOCS2-overexpressing mice and SOCS2-deficient mice exhibit an excess growth phenotype (Tan and Rabkin, 2005) . Our observation of DON-induced SOCS2 in mice is notable because SOCS2-deficient mice exhibit increased expression of peroxisome proliferators-activated receptor-gamma coactivator 1 alpha (PGC-1a) in their skeletal muscles suggesting that SOCS2 may have a role in the transcription of this metabolic regulator. SOCS2 deficiency in mice also causes a gigantism associated with muscle PGC-1a upregulation, whereas DON exposure causes SOCS2 upregulation and impairment of weight gain. It might be speculated that DON-induced impairment of weight gain is related to PGC-1a reduction, however, this requires further investigation.
Hepatic SOCS3 upregulation was the most robust indicator of DON exposure among the SOCS analyzed. SOCS3 protein staining in hepatocytes confirmed that liver is indeed another target organ for DON effects. SOCS3 shares a kinase inhibitory region with SOCS1, and is effective in binding intracellular kinases on the IL-6 family receptors (Tan and Rabkin, 2005) . SOCS3 inhibits GH signaling in vitro and mediates IL-6 impairment of GH signaling in vivo . DON induces IL-6 and IL-6 induces hepatic SOCS3 Wormald et al., 2006) . Thus, one explanation for the pronounced SOCS3 increase might be the marked induction of IL-6 by DON . IL-6 might originate in liver and exert its response in an autocrine or paracrine manners, or it could be produced by distant organs (e.g., spleen and lung) and exert its hepatic effects in an endocrine fashion. However, it should be noted that other 
DON-INDUCED SOCS EXPRESSION
proinflammatory cytokines such as IL-1b and TNF-a also induce SOCS3 (Alexander, 2002) , albeit to a lesser degree than IL-6. The redundancy exhibited among cytokine signaling networks presents a major challenge in determining a specific cytokine inducer of hepatic SOCS3. Regardless of which cytokines are upstream, the peak of hepatic SOCS3 protein upregulation (4-5 h) appears to be later than that of circulating proinflammatory cytokines (2-3 h), indicating that SOCS3 might have an impact on downstream consequences of DON exposure like growth reduction.
The reason for centrilobular zonation of DON-induced SOCS3 is not clear, but is consistent with SOCS3 expression in another model of SOCS induction in the liver (Ogata et al., 2006) . Zonation of metabolic enzymes, physiological responses, and oxygen tension occur in the liver (Jungermann and Kietzmann, 2000) and might contribute to zonation of toxicant effects. Centrilobular SOCS3 expression suggests that either the eliciting cytokines are more concentrated around the central vein or the necessary cytokine receptors are more abundant around the central vein. These possibilities are not mutually exclusive and highlight a complexity of hepatocyte responses that needs to be resolved in future studies. Nevertheless, sensitive and sustained SOCS3 expression in hepatocytes is consistent with its negative regulatory role and could conceivably attenuate hepatic GH signaling.
SOCS characterization offers an integrative approach to study potential metabolic effects of nonhepatotoxic immunotoxicants. For example, previous subchronic and chronic DON studies have reported an unexplained but significant reduction in liver weights (Forsell et al., 1986; Iverson et al., 1995) , without overt hepatotoxicity. Because SOCS proteins impair cell proliferation and growth, it is possible that the observed FIG. 8 . Kinetics of SOCS3 protein expression in the liver. Mice were exposed to DON and PBS (vehicle) , as in Figure 4 above. Histologic sections of the liver were taken at 2, 3, 4, and 5 h after DON exposure (A, B, C, and D, respectively); and 3, 5 h after vehicle exposure (E and F, respectively). Paraffin-embedded sections were immunohistochemically stained for SOCS3 and counterstained with hematoxylin after DAB reaction. Arrows indicate areas of SOCS3 protein staining. Bar ¼ 50 lm. 284 reduction of liver weight is a result of continuous/episodic hepatic SOCS upregulation, resulting in a proliferative disadvantage. Another observation supporting an antiproliferative hypothesis is that spontaneous preneoplastic liver lesions are reduced in DON-fed mice when compared with age-matched controls after 2 years of DON feeding (Iverson et al., 1995) . Thus, this unexplained DON effect in the liver could be further studied in the context of altered SOCS signaling.
In summary, the robust systemic induction of SOCS mRNA and protein by DON is a novel finding for natural foodborne toxin. The kinetics of DON-induced SOCS expression relative to proinflammatory cytokines indicates that DON induces cytokines, in spleen and liver first (1 h) and SOCS3 later (2 h). SOCS3 remains upregulated after cytokines have returned to basal levels, and is associated with a suppression of hepatic IGFALS. Accordingly, studies of SOCS signaling offers the opportunity to integrate previously reported immune effects of DON and other toxins into a metabolic context, involving the liver and other organs. Such investigations could facilitate improved understanding of the mechanism(s) for weight gain reduction and lead to identification of novel biomarker(s) of effect for human risk assessment.
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